-
公开(公告)号：KR1020130089030A
公开(公告)日：2013-08-09
申请号：KR1020120010355
申请日：2012-02-01
Applicant: 강원대학교산학협력단
IPC: A61K31/404 , A61K31/40 , A61P35/00
CPC classification number: A61K31/409
Abstract: PURPOSE: A pharmaceutical composition for overcoming resistance to an anticancer agent is provided to suppress the activity of hemo oxygenase (HO) increased in cancer cells using methyl pheophorbide (MPP), thereby remarkably increasing apoptotic sensitivity in cancer cells with anticancer agent resistance. CONSTITUTION: A pharmaceutical composition for overcoming resistance to an anticancer agent contains MPP as an active ingredient. The anticancer agent is cisplatin. The effective concentration of MPP is 10 uM. A composition for suppressing HO contains MPP as an active ingredient.
Abstract translation: 目的：提供一种克服抗癌剂抗性的药物组合物，以抑制癌细胞中使用甲基偏硼酸（MPP）增加的血红素加氧酶（HO）的活性，从而显着增加抗癌剂抗性的癌细胞的凋亡敏感性。 构成：克服抗癌剂抗性的药物组合物含有MPP作为活性成分。 抗癌剂是顺铂。 MPP的有效浓度为10uM。 用于抑制HO的组合物含有MPP作为活性成分。
-
公开(公告)号：KR101140391B1
公开(公告)日：2012-05-03
申请号：KR1020110031539
申请日：2011-04-06
Applicant: 강원대학교산학협력단
Abstract: PURPOSE: A method for screening a material containing a material with anti-obesity or anti-inflammatory activities using HO-1 protein is provided. CONSTITUTION: A method for reducing adipocyte differentiation comprises a step of overexpressing heme oxidase-1 genes in heme oxidase-1 gene-overexpressing adipocytes prepared by introducing a recombinant vector containing heme oxidase-1 gene with a base sequence of sequence number 1 into precursor adipocyte cell line. A method for searching an anti-obesity candidate from natural products comprises: a step of treating the natural products to the heme oxidase-1 gene overexpressing adipocytes; a step of measuring expression level of the heme oxidase-1 gene; and a step of selecting a natural product as an anti-obesity candidate in case that the heme oxidase-1 gene expression is reduced.
Abstract translation: 目的：提供使用HO-1蛋白筛选含有抗肥胖或抗炎活性物质的材料的方法。 构成：减少脂肪细胞分化的方法包括通过将含有序列1的碱基序列的含有血红素氧化酶-1基因的重组载体导入前体脂肪细胞而制备的血红素氧化酶-1基因过表达的脂肪细胞中过表达血红素氧化酶-1基因的步骤 细胞系。 从天然产物中搜索抗肥胖症候选者的方法包括：将天然产物处理过量表达脂肪细胞的血红素氧化酶-1基因的步骤; 测定血红素氧化酶-1基因表达水平的步骤; 在血红素氧化酶-1基因表达降低的情况下选择天然产物作为抗肥胖症候选者的步骤。
-
-
公开(公告)号：KR1020120003832A
公开(公告)日：2012-01-11
申请号：KR1020110122052
申请日：2011-11-22
Applicant: 강원대학교산학협력단
IPC: A61K38/16 , A61K31/711 , A61P35/00
Abstract: PURPOSE: A composition containing NADPH oxidase complex protein and/or diphenylene iodonium and/or derivative thereof is provided to treat and diagnose cancer. CONSTITUTION: A composition for preventing and treating cancer contains therapeutically effective amount of diphenylene iodonium, derivative thereof, or pharmaceutically acceptable salt thereof as an active ingredient. The therapeutically effective amount is 1mg/kg to 1000 mg/kg. The composition is administered by combining with an anti-cancer drug such as cisplatin, taxol, taxotere, doxorubicin, etoposide, gleevec, arimidex, tamoxifern, epirubicin, adriamycin, or valstar.
Abstract translation: 目的：提供含有NADPH氧化酶复合蛋白和/或二亚苯基碘和/或其衍生物的组合物以治疗和诊断癌症。 构成：用于预防和治疗癌症的组合物含有治疗有效量的二亚苯基碘鎓，其衍生物或其药学上可接受的盐作为活性成分。 治疗有效量为1mg / kg至1000mg / kg。 组合物通过与抗癌药物如顺铂，紫杉醇，泰索帝，多柔比星，依托泊苷，格列卫，阿昔洛韦，他莫昔芬，表柔比星，阿霉素或valstar组合施用。
-
公开(公告)号：KR1020120114140A
公开(公告)日：2012-10-16
申请号：KR1020110103166
申请日：2011-10-10
Applicant: 강원대학교산학협력단
Abstract: PURPOSE: A method for preparing recombinant plasmid using heme oxidase-1 gene is provided to screen natural products with anti-obesity and/or anti-inflammatory functions. CONSTITUTION: A recombinant plasmid is used for suppressing the expression of heme oxidase-1 gene. A plasmid vector contains an RNA promoter. The hame oxidase-1 gene has a base of sequence number 1. A base for inducing hairpin structure is a base of sequence number 2 or 3. A method for producing adipocytes which suppresses heme oxidase-1 gene expression comprises a step of transduction of the recombinant plasmid to adipocyte cell line. A method for detecting an anti-obesity candidate from a natural product comprises: a step of treating the natural product to the adipocytes; a step of measuring the expression level of the heme oxidase-1 gene; and a step of selecting the natural product as an anti-obesity candidate material when the expression of heme oxidase-1 gene is reduced. [Reference numerals] (AA) Beta-actin
Abstract translation: 目的：提供使用血红素氧化酶-1基因制备重组质粒的方法，筛选具有抗肥胖和/或抗炎功能的天然产物。 构成：重组质粒用于抑制血红素氧化酶-1基因的表达。 质粒载体含有RNA启动子。 hame氧化酶-1基因具有序列号1的碱基。用于诱导发夹结构的碱基是序列号2或3的碱基。一种抑制血红素氧化酶-1基因表达的脂肪细胞的制备方法包括转导 重组质粒到脂肪细胞系。 从天然产物检测抗肥胖症候选物的方法包括：将天然产物处理至脂肪细胞的步骤; 测定血红素氧化酶-1基因表达水平的步骤; 并且当血红素氧化酶-1基因的表达降低时，选择天然产物作为抗肥胖候选物质的步骤。 （参考号）（AA）β-肌动蛋白
-
Patent Agency Ranking
公开(公告)号：KR1020110088733A
公开(公告)日：2011-08-04
申请号：KR1020100008374
申请日：2010-01-29
Applicant: 강원대학교산학협력단
IPC: A61K38/16 , A61K31/711 , A61P35/00
CPC classification number: A61K38/16 , G01N2800/365
Abstract: PURPOSE: A composition containing NADPH oxidase composite protein is provided to induce apoptosis of cancer cells and to treat and diagnose cancer. CONSTITUTION: A composition for diagnosing cancer contains polypeptides selected from the group consisting of NADPH oxidase composite(Nox) 1, NADPH oxidase complex(Nox)4, and NADPH oxidase composite(Nox) 5, and functional mutants as an active ingredient. The Nox 1, Nox 4, and Nox 5 have an amino acid sequence of sequence numbers 19, 20, and 21.
Abstract translation: 目的：提供含有NADPH氧化酶复合蛋白的组合物诱导癌细胞凋亡并治疗和诊断癌症。 构成：用于诊断癌症的组合物含有选自NADPH氧化酶复合物（Nox）1，NADPH氧化酶复合物（Nox）4和NADPH氧化酶复合物（Nox）5的多肽和作为活性成分的功能性突变体。 Nox 1，Nox 4和Nox 5具有序列号19,20和21的氨基酸序列。
-
7.发明授权
公开(公告)号：KR101489844B1
公开(公告)日：2015-02-06
申请号：KR1020130074658
申请日：2013-06-27
Applicant: 강원대학교산학협력단 , 가천대학교 산학협력단
IPC: A01K67/027 , C12N15/12 , G01N33/15
Abstract: 본 발명은 14-3-3 시그마 유전자 결손 마우스, 이를 이용한 인 비보 패혈증 연구모델 개발 방법 및 그 응용에 관한 것이다.
-
8.发明公开14-3-3 시그마 유전자 결손 마우스, 이를 이용한 인 비보 패혈증 연구모델 개발 방법 및 그 응용 有权14-3-3 SIGMA NULL鼠标，使用其同样的和使用它的体内冲击研究模型的发展
公开(公告)号：KR1020150001435A
公开(公告)日：2015-01-06
申请号：KR1020130074658
申请日：2013-06-27
Applicant: 강원대학교산학협력단 , 가천대학교 산학협력단
IPC: A01K67/027 , C12N15/12 , G01N33/15
CPC classification number: A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/0368 , G01N33/15
Abstract: 본 발명은 14-3-3 시그마 유전자 결손 마우스, 이를 이용한 인 비보 패혈증 연구모델 개발 방법 및 그 응용에 관한 것이다.
Abstract translation: 本发明的目的是开发体内脓毒症研究模型。 本发明涉及一种缺乏14-3-3的sigma基因的小鼠，用于开发使用该小鼠的体内脓毒症研究模型的方法及其用途。 此外，本发明的方法包括以下步骤：用测试材料处理缺少14-3-3个sigma基因的转基因小鼠; 并且在测试材料存在的情况下测量转基因小鼠的存活率，其中14-3-3 sigma基因优选具有序列号1的碱基序列，但是所有突变基因具有一个或多个取代基 ，基因上的缺失，倒位和/或易位突变都包括在本发明的范围内。
-
公开(公告)号：KR1020140102441A
公开(公告)日：2014-08-22
申请号：KR1020130015715
申请日：2013-02-14
Applicant: 강원대학교산학협력단
CPC classification number: A61K48/00 , A61K38/16 , Y10S514/886
Abstract: The present invention relates to an anti-inflammatory composition comprising 14-3-3 sigma gene and/or protein as an active ingredient. The 14-3-3 sigma gene is preferred to be composed of a base sequence of SEQ ID NO.1; and provided in the present invent is an anti-inflammatory composition comprising a 14-3-3 sigma protein as an active ingredient. In an embodiment of the present invention, the 14-3-3 sigma protein is preferred to be composed of a base sequence of SEQ ID NO. 2, but is not limited to the same; and provided in the present invention is an expression vector controlling inflammatory cytokine comprising the 14-3-3 sigma gene composed of SEQ ID NO.1 as an active ingredient.
Abstract translation: 本发明涉及包含14-3-3σ基因和/或蛋白质作为活性成分的抗炎组合物。 14-3-3 sigma基因优选由SEQ ID NO.1的碱基序列组成; 并且在本发明中提供的是包含14-3-3σ蛋白作为活性成分的抗炎组合物。 在本发明的一个实施方案中，14-3-3σ蛋白质优选由SEQ ID NO.1的碱基序列组成。 2，但不限于此; 在本发明中提供了控制炎性细胞因子的表达载体，其包含由SEQ ID NO.1组成的14-3-3 sigma基因作为活性成分。
-
公开(公告)号：KR101356139B1
公开(公告)日：2014-01-24
申请号：KR1020110103166
申请日：2011-10-10
Applicant: 강원대학교산학협력단
Abstract: 본 발명은 HO-1 단백질의 항비만 관련 기능을 검증하고 ho-1 유전자 발현 조절 시스템을 도입한 전구체 지방세포주 제작 및 이를 탐색 시스템으로 사용하여 항비만 또는 항염증 활성을 함유하는 물질의 스크리닝 방법에 관한 것이다.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.023 seconds)
